Reproducible Molecular Subtypes in Systemic Lupus Erythematosus Are Associated With Disease Activity, Serology, and Distinct Trajectories Over Time - Report - MDSpire

Consistent Molecular Subtypes in Systemic Lupus Erythematosus Correlate With Disease Activity, Serological Profiles, and Unique Longitudinal Patterns

  • By

  • Loqmane Seridi

  • Eugene Myshkin

  • Erika Noss

  • Sheng Gao

  • Julio Molineros

  • Carolyn Cuff

  • Dawn Waterworth

  • Matthew J. Loza

  • July 1, 2026

Share

Clinical Report: Consistent Molecular Subtypes in Systemic Lupus Erythematosus

Overview

This study identifies robust molecular subtypes in systemic lupus erythematosus (SLE) using three large cohorts, revealing correlations with disease activity and serological profiles.

Background

Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by diverse manifestations that complicate diagnosis and treatment. Molecular stratification approaches are essential for improving patient subtyping and developing targeted therapies.

Data Highlights

No numerical data or trial data provided in the source material.

Key Findings

  • Three large SLE cohorts were utilized to identify molecular subtypes.
  • Molecular subtypes correlated with disease activity and serological profiles.
  • IFN signatures were linked to renal involvement in SLE patients.
  • B cell/plasmablast activation was associated with serologic activity.
  • Longitudinal stability and clinical improvement were evaluated in the LOTUS cohort.

Clinical Implications

Clinicians should consider molecular profiles when assessing disease activity and treatment responses.

Conclusion

Further research is necessary to validate these findings across diverse patient populations.

Related Resources & Content

  1. Conexiant, Source, 2023 -- Lab Markers May Guide Lupus Biologic Use
  2. Frontiers in Immunology, Source, 2026 -- Distinct IgM and IgG autoantibody profiles characterize incomplete and classified systemic autoimmune diseases
  3. Clinical Rheumatology, Source, 2025 -- The Role of Serum APRIL, BAFF, and IL-10 Levels in Assessing Disease Activity and Flare Prediction in Systemic Lupus Erythematosus Is Limited
  4. Clinical Rheumatology, Source, 2025 -- Bioinformatics Integration and Clinical Validation Identify PRDX6 as a Key Mitochondrial Gene in Systemic Lupus Erythematosus
  5. Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus | New England Journal of Medicine, Source, 2026
  6. Reproducible Molecular Subtypes in Systemic Lupus Erythematosus Are Associated With Disease Activity, Serology, and Distinct Trajectories Over Time - Seridi - 2026 - ACR Open Rheumatology - Wiley Online Library
  7. https://rheumatology.org/api/asset/bltec93920aad624e33
  8. Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus | New England Journal of Medicine
  9. Reproducible Molecular Subtypes in Systemic Lupus Erythematosus Are Associated With Disease Activity, Serology, and Distinct Trajectories Over Time - Seridi - 2026 - ACR Open Rheumatology - Wiley Online Library

Original Source(s)

Related Content